Clinical observation of HEPP regimen in treatment of refractory Non-Hodgkin lymphoma
- VernacularTitle:HEPP方案治疗难治性非霍奇金淋巴瘤的临床观察
- Author:
Feng WANG
;
Jun QIAN
;
Shukui QIN
;
Yingxia CHEN
;
Zeming HE
;
Lin WANG
- Publication Type:Journal Article
- Keywords:
HEPP regimen;
Non-Hodgkin's lymphoma;
HCPT;
VP16;
PDD;
PDN
- From:
Cancer Research and Clinic
1997;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the short-term efficacy and toxicity of HEPP regimen in treatment of refractory Non-Hodgkin's Lymphoma. Methods HEPP regimen: HCPT 8 mg/m2 iv gtt d1~ d5, VP16 100 mg/d iv gtt d1~d5, PDD 20 mg/d iv gtt d1~d5, PDN 60 mg/m2 po d1~d14. The chemotherapy was repeated every 4 weeks as a cycle.The clinical effect was evaluated after 2 cycles and toxicity was observed during every cycle. Results 25 patients were eligible for toxicity evaluation and 22 patients for clinical response evaluation. The objective response rate was 60.0 %, including three cases complete remission and ten cases partial remission. Six cases achieved stable disease and three cases progressive disease. The major toxicity was bone marrow suppression, including 24.0 % grade Ⅲ/Ⅳ leukopenia and 12.0 % grade Ⅲ/Ⅳ thrombocytopenia. The incidence of nausea/vomiting, mucositis and hepatic toxicity was low. Conclusion HEPP regimen can achieve a satisfy result in the treatment of refractory Non-Hodgkin's Lymphoma. It is low toxic and well tolerated.
